The Working Group Leaders and Nucleus members worked with the leadership of the ISHLT Pulmonary Hypertension Council to develop a fantastic session on Pulmonary Hypertension in Left Heart Disease.
The session is on Wednesday, April 27th at 10:15 am. It will involve controversial topics, clinical cases, and panel discussion. Please find below details of the session.
Marriott Wardman Park, Salon 1
Co-Chair: Stavros Konstantinides, MD, PhD, FESC
Co-Chair: Mardi Gomberg-Maitland, MD
PH- Left Heart Disease: Defining Group 2 PH
Irene Lang, MD, Medical University of Vienna, Vienna, Austria
Description: This will be an overview to set the stage for the entire session. The epidemiology, definition of PH-Group 2, pathophysiology, and diagnostics will be discussed.
Is All Heart Failure the Same on the Pulmonary Circulation, and How Does It Impact Survival?
Nazzareno Galiè, MD, Bologna University Hospital, Bologna, Italy
Description: Discussion of all causes PH LHD: obstruction, congenital etc and its effects on the pulmonary circulation. Discuss the prognosis of the different types and perhaps if the survival is dependent on its vascular effects. Discuss how this is seen diagnostically.
Monitoring and Therapeutic Options for Pulmonary Hypertension in Left Heart Disease
Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
Description: Discussion of current/future therapies and monitoring of PH/LHD: cardiomems, oral therapies, and potential mechanical support.
Provocative Testing in Pulmonary Hypertension in Left Heart Disease
Robert Naeije, MD, Free University of Brussels, Brussels, Belgium
Description: Dr. Naeije will use a case based approach to discuss the importance of provocative testing in selected patient with suspected PH-LHD. Specifically, he will discuss the roles of volume loading and exercise as part of his presentation.
DEBATE: Diastolic Pulmonary Gradient is a Marker of Pulmonary Vasculopathy in Pulmonary Hypertension in Left Heart Disease (PRO)
Jean-Luc Vachiery, MD, Erasme University Hospital - ULB, Brussels, Belgium
Description: Give the evidence to support that the diastolic pulmonary gradient is a marker of pulmonary vasculopathy in pulmonary hypertension from left heart disease.
DEBATE: Diastolic Pulmonary Gradient is a Marker of Pulmonary Vasculopathy in Pulmonary Hypertension in Left Heart Disease (CON)
Stephan Rosenkranz, MD, Herzzentrum der Universität zu Köln, Cologne, Germany
Description: Provide the evidence that DPG is not a marker of pulmonary vasculopathy in PH-left heart disease.
DEBATE REBUTTAL (PRO)
DEBATE REBUTTAL (CON)
A Challenging Case of Pulmonary Hypertension
Myung H. Park, MD, Houston Methodist, Houston, TX, USA
Description: The speaker will select a clinical case that will highlight the difficulties in differentiating the types of PH.
Description: The best diagnostic and therapeutic strategies from the above case will be discussed by the ISHLT/ESC session speakers and chairs.
Access the ISHLT Annual Meeting full Programme
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 Biot
06903 Sophia Antipolis, FR
Washington DC, USA
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved